178 related articles for article (PubMed ID: 19657689)
1. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
Kendler DL; Bessette L; Hill CD; Gold DT; Horne R; Varon SF; Borenstein J; Wang H; Man HS; Wagman RB; Siddhanti S; Macarios D; Bone HG
Osteoporos Int; 2010 May; 21(5):837-46. PubMed ID: 19657689
[TBL] [Abstract][Full Text] [Related]
2. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
3. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Gold DT; Horne R; Coon CD; Price MA; Borenstein J; Varon SF; Satram-Hoang S; Macarios D
Value Health; 2011 Dec; 14(8):1109-16. PubMed ID: 22152181
[TBL] [Abstract][Full Text] [Related]
4. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
5. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
6. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.
Kendler DL; Macarios D; Lillestol MJ; Moffett A; Satram-Hoang S; Huang J; Kaur P; Tang ET; Wagman RB; Horne R
Menopause; 2014 Jan; 21(1):25-32. PubMed ID: 23676636
[TBL] [Abstract][Full Text] [Related]
7. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Hadji P; Minne H; Pfeifer M; Bourgeois P; Fardellone P; Licata A; Devas V; Masanauskaite D; Barrett-Connor E
Joint Bone Spine; 2008 May; 75(3):303-10. PubMed ID: 18069036
[TBL] [Abstract][Full Text] [Related]
8. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
[TBL] [Abstract][Full Text] [Related]
10. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
12. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
[TBL] [Abstract][Full Text] [Related]
13. Denosumab (prolia) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
[No Abstract] [Full Text] [Related]
14. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
19. [Denosumab--a new efficient osteoporosis therapy].
Rejnmark L; Vestergaard P; Mosekilde L
Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]